Kingdon Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kingdon Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-125,000	Closed	-$7.4M	–	143
2016 Q4	$7.4M	Buy	+125,000	New	+$7.72M	0.36%	75

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

CHP

Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Kingdon Capital Management's XBI Position: Q1 2017 in Review

Kingdon Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 125,000 shares — an estimated $7.4M sold.

Kingdon Capital Management first reported a position in XBI in Q4 2016 and held it in 1 quarter. The position peaked at $7.4M in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Kingdon Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Kingdon Capital Management sold 125,000 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $7.4M.
Kingdon Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 1 quarter.
Kingdon Capital Management's State Street SPDR S&P Biotech ETF position peaked at $7.4M in Q4 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.